Summary:
The purpose of this research study is to evaluate the next-dose trasnition from Zolpidem (Ambien) to Lemborexant for the treatment of insomnia.
Qualified Participants Must:
Be 18 years or older, currently taking Zolpidem (Ambien) and spend more than 7 hours a night in bed